查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球子宮內膜異位症藥物市場-2022-2029
市場調查報告書
商品編碼
1143408

全球子宮內膜異位症藥物市場-2022-2029

Global Endometriosis Drug Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

預計 2018 年子宮內膜異位症治療市場的市場規模將達到 18.0778 億美元，預計在 2022-2029 年的預測期內以 10.4% 的複合年增長率增長。

子宮內膜異位症是一種疼痛性疾病，其中與通常排列在子宮內的組織（子宮內膜）相似的組織在子宮外生長。子宮內膜異位症最常影響卵巢、輸卵管和盆腔組織。子宮內膜異位症很少發生在盆腔器官區域之外。

市場動態

推動市場增長的主要因素是對這種疾病的認識提高、口服避孕藥的普及以及由於診斷技術的改進導致子宮內膜異位症患者的增加。

隨著子宮內膜異位症負擔的增加，意識的提高和新產品的開發正在推動全球市場的增長。

根據世界衛生組織的數據，子宮內膜異位症影響全球約 10%（1.9 億）的育齡婦女和女孩。此外，據英國 ENDOMETRIOSIS 統計，英國每 10 名育齡婦女中就有 1 名患有子宮內膜異位症，而不孕婦女的子宮內膜異位症患病率高達 30-50%，是美國第二常見的婦科疾病。 ，影響 150 萬人。這與每年在治療、失業和醫療費用方面花費英國經濟 82 億英鎊的糖尿病患者人數大致相同。此外，提高診斷和治療水平的努力也在推動全球市場。歐洲研究人員制定了新的子宮內膜異位症診斷和治療指南，顯著更新了管理該疾病的五個關鍵領域，包括診斷、治療和復發。

提高對子宮內膜異位症認識的努力也有助於全球市場的增長。 2022 年 3 月 12 日，隨著奧地利子宮內膜異位症協會 (EVA) 舉辦了第二次為期一天的免費子宮內膜異位症在線會議，世衛組織正在與民間社會和子宮內膜異位症宣傳團體合作。我們合作並參與宣傳和支持的努力。研究人員還在努力更好地了解這種疾病及其症狀，以改善診斷和治療。例如，新診斷方法的開發，例如 Ziwig SAS 於 2022 年 2 月 11 日推出的用於快速檢測子宮內膜異位症的“Endotest”唾液測試，是無創、易於使用且存在於唾液中的。研究下一代 microRNA 測序，並運用人工智能產生的海量數據。

無效的藥物治療和低成功率正在抑制全球子宮內膜異位症藥物市場的增長。

然而，藥物治療無效和成功率低是製約市場增長的主要因素。

COVID-19 影響分析

在 COVID-19 大流行期間，意識訓練營被取消或推遲或轉為在線模式，由於採取了社交距離等規定來控制病毒，因此減少了人口池。此外，大多數研究設施被關閉或降級，延長了研究項目。此外，由於難以進行定期婦科醫生檢查，大多數子宮內膜異位症患者未被發現，在大流行期間對全球市場產生負面影響。

細分分析

在預測期內（2022-2029），激素治療有望對子宮內膜異位症藥物市場產生較大影響

激素療法將在 2021 年佔據全球市場的最大份額，並且由於臨床研究和新產品開發的增加，預計將在整個預測期內（2022-2029 年）佔據主導地位。例如，clinicaltrials.gov 目前有四項干預試驗調查激素治療子宮內膜異位症。例如，由美國大學貝魯特醫學中心、維克森林大學健康科學學院贊助的一項試驗評估地諾孕素與 GnRH-a 對接受體外受精的子宮內膜異位症女性的調理，預計結束日期為 2023 年 2 月 22 日。我們資助的生育力增強臨床試驗（EFFECT），預計將於 2022 年 12 月完成。此外，2021 年 5 月 26 日，美國食品藥品監督管理局 (FDA) 批准 MYFEMBREE（relgolix 40 mg，雌二醇 1 mg，醋酸去甲腎上腺素 0.5 mg）作為首個每日一次的子宮內膜異位症治療藥物，正在進行中。

區域分析

預計北美將主導全球子宮內膜異位症藥物市場。

北美將在 2021 年主導全球市場，由於該地區子宮內膜異位症的高發率，預計將在整個預測期間（2022-2029 年）佔據主導地位。例如，根據約翰霍普金斯醫學院的數據，子宮內膜異位症估計會影響 2-10% 的 25-40 歲的美國女性。根據女性健康辦公室的數據，超過 11% 的美國 15 至 44 歲女性患有子宮內膜異位症。此外，在北美，許多提高對子宮內膜異位症認識的政府和非政府組織的存在有助於該地區在全球市場上的主導地位。此外，佔據大部分市場份額的Pfizer Inc., Johnson & Johnson, Merck & Co., Inc., Eli Lilly and Company, AbbVie等主要市場參與者均位於美國，佔比最大預測期內全球子宮內膜異位症藥物的市場份額，確保了北美市場的主導地位。

競爭格局

全球子宮內膜異位症藥物市場競爭激烈，可能是由於主導市場的大型藥物管道。一些主要參與者包括 Eli Lilly and Company, Pfizer Inc., Bayer, AstraZeneca, Novartis AG, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Johnson & Johnson Services, INC., AbbVie, GlaxoSmithKline plc. 。這些公司通過技術創新、產品發布、合作研究、收購和合作獲得主要市場份額。例如，2022 年 8 月 16 日，GlaxoSmithKline plc.收購了 Affinivax, Inc.。此外，2021 年 12 月 22 日，Novartis AG將收購 Gyroscope Therapeutics。

  • AstraZeneca

    • 概述

    AstraZenecaplc 成立於 1999 年，總部位於英國劍橋。 AstraZeneca plc 是癌症、心血管、胃腸道、傳染病、神經科學、呼吸和炎症領域的領先製藥和生物技術公司。

    產品組合

    AstraZenecaplc 的子宮內膜異位症產品組合包括 ZOLADEX。

    全球子宮內膜異位症藥物報告將提供大約 40 多個市場數據表、45+ 個數字和 200 頁（大約）的區域。.

    內容

    第一章研究方法與範圍

    • 調查方法
    • 調查目的和範圍

    第 2 章市場定義和概述

    第 3 章執行摘要

    第 4 章市場動態

    • 市場影響因素
      • 驅動程序
        • 增加對子宮內膜異位症的負擔和認識
        • 研發
      • 約束因素
        • 開發成本高
        • 無效的藥物治療
      • 商機
      • 影響分析

    第五章行業分析

    • 波特五力分析
    • 供應鏈分析
    • 監管分析
    • 管道分析
    • 流行病學分析

    第 6 章 COVID-19 分析

    • COVID-19 的市場分析
      • COVID-19 之前的市場情景
      • COVID-19 的當前市場情景
      • COVID-19 後或未來情景
    • COVID-19 期間的價格動態
    • 供需範圍
    • 大流行期間與市場相關的政府舉措
    • 製造商的戰略舉措
    • 總結

    第 7 章按類型

    • 腹膜淺表病變
    • 子宮內膜異位症
    • 深浸潤性子宮內膜異位症
    • 其他

    第 8 章按治療類型

    • 激素療法
    • 疼痛管理
    • 其他

    第 9 章給藥途徑

    • 口語
    • 腸胃外
    • 其他

    第 10 章，最終用戶

    • 醫院和診所
    • 居家護理
    • 其他

    第 11 章按地區劃分

    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲
    • 亞太地區
      • 中國
      • 印度
      • 日本
      • 澳大利亞
      • 其他亞太地區
    • 中東和非洲

    第 12 章競爭格局

    • 主要發展和戰略
    • 公司份額分析
    • 產品基準

    第 13 章公司簡介

    • AstraZeneca
      • 公司簡介
      • 產品組合和描述
      • 主要亮點
      • 財務摘要
    • Eli Lilly and Company
    • Pfizer Inc.
    • Bayer
    • Novartis AG
    • Merck & Co., Inc.
    • Boehringer Ingelheim International GmbH
    • Johnson & Johnson Services, INC.
    • AbbVie
    • GlaxoSmithKline plc.（*未詳盡列出）

    第 14 章數據M

    簡介目錄
    Product Code: DMPH132

    Market Overview

    Endometriosis Drug Market is estimated to reach a market value of USD 1807.78 million by 2018 and the market is estimated to grow at a CAGR of 10.4% in the forecasted period 2022-2029.

    Endometriosis is a painful ailment in which tissue analogous to the tissue that usually lines the inside of the uterus (endometrium) grows outside the uterus. Endometriosis most commonly involves ovaries, fallopian tubes, and the tissue lining pelvis. Endometriosis is rarely encountered outside the area of the pelvic organs.

    Market Dynamics

    Increased awareness about the disease, growing trend in the adoption of the oral contraceptive pill, and increased incidents of endometriosis due to improved diagnostics techniques are some of the major factors driving the market's growth.

    With the increasing burden of endometriosis, awareness and new product developments drive global market growth.

    According to the WHO, Endometriosis affects roughly 10% (190 million) of reproductive age women and girls globally; also, as per the ENDOMETRIOSIS UK, 1 in 10 women of reproductive age in the UK suffer from endometriosis, and the prevalence of endometriosis in women with infertility be as high as to 30-50% making it the second most common gynecological condition in the UK affecting 1.5 million women, a similar number of those affected by diabetes which costs the UK economy £8.2bn a year in treatment, loss of work and healthcare costs. Moreover, the increased efforts to improve the diagnosis and treatment drive the global market. European researchers have created new guidelines for diagnosing and treating endometriosis and have significantly updated five key areas in managing the condition, including diagnosis, treatment, and recurrence, which will help patients and clinicians better understand and manage the condition.

    The rising efforts to spread awareness about endometriosis are also contributing to the global market growth; like the Endometriosis Association Austria (EVA) On 12 March 2022 hosted a free, full-day, online congress on endometriosis for the second time, WHO collaborated with civil society and endometriosis patient support groups to join the effort of spreading awareness and support. Researchers have also been working to understand the disease and its symptoms better to improve diagnosis and treatment. For instance, the development of a new diagnostic method like the Endotest saliva test for quickly detecting endometriosis by Ziwig SAS launched on 11 February 2022, which is a non-invasive and easy-to-use test and relies on Next-generation Sequencing of micro-RNA present in saliva and with the artificial intelligence to exercise the large amount of data generated.

    Ineffective drug therapies and poor success rates restrain the global endometriosis drug market growth.

    However, ineffective drug therapies and poor success rates are the major factors restraining the market's growth.

    COVID-19 Impact Analysis

    During the COVID-19 pandemic, the awareness camps were either canceled or postponed or switched to online mode, reducing the population pool as regulations such as social distancing was employed to contain the virus. Furthermore, most research facilities were shut down or working on a reduced force, which prolonged the research project. Moreover, regular gynecologist checkups were difficult, leaving most endometriosis patients undetected, negatively impacting the global market during the pandemic.

    Segment Analysis

    Hormone therapy is expected to have a greater grasp on the endometriosis drug market during the forecast period (2022-2029)

    Hormone therapy accounted for the largest share of the global market during 2021 and is expected to dominate throughout the forecast period (2022-2029) owing to the increasing clinical research and new product developments. For instance, as per clinicaltrials.gov, currently, 4 interventional trials are recruiting to study hormonal treatment for endometriosis, such as a study to evaluate the Dienogest versus GnRH-a pre-treatment in women with endometriosis undergoing IVF, sponsored by American University of Beirut Medical Center with an estimated study completion date of February 22, 2023, and a study of Elagolix for fertility enhancement clinical trial (EFFECT) financed by Wake Forest University Health Sciences and estimated to be finished by December 2022. Furthermore, the launch of new products such in May 26, 2021, the U.S. Food and Drug Administration (FDA) approved MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg), the first once-daily treatment for endometriosis.

    Geographical Analysis

    North America is expected to command dominating the global endometriosis drug market.

    North America dominated the global market in 2021 and is expected to dominate throughout the forecast period (2022-2029) owing to the high prevalence of endometriosis in this region. For instance, according to Johns Hopkins Medicine, endometriosis affects an estimated 2% to 10% of American women aged 25-40. Also, as per Office on Women's Health, more than 11% of American women between 15 and 44 are affected by endometriosis. Furthermore, the presence of many government and non-government organizations spreading awareness about endometriosis in North America contributes to the dominance of this region over the global market. Moreover, the key market players such as Pfizer Inc., Johnson & Johnson, Merck & Co., Inc., Eli Lilly and Company and AbbVie, holding a majority of the market share, are US based, ensuring the command of North America over the global endometriosis drug market during the forecast period.

    Competitive Landscape

    The global endometriosis drug market is competitive because of a large drug pipeline, which will probably dominate the market. Some key players are Eli Lilly and Company, Pfizer Inc., Bayer, AstraZeneca, Novartis AG, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Johnson & Johnson Services, INC., AbbVie and GlaxoSmithKline plc. These players hold the major share of the market through innovations, product launches, collaborations, acquisitions, and performing alliances. For instance, in August 16, 2022, GSK acquired Affinivax, Inc. Also, in December 22, 2021, Novartis acquired Gyroscope Therapeutics.

    AstraZeneca plc

    Overview:

    AstraZeneca plc was founded in 1999 and is headquartered in Cambridge, UK. AstraZeneca plc is a leading pharmaceutical and biotechnology company dealing with oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

    Product Portfolio:

    The product portfolio of AstraZeneca plc for endometriosis drugs has ZOLADEX.

    The global endometriosis drug report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

    Table of Contents

    1. Methodology and Scope

    • 1.1. Research Methodology
    • 1.2. Research Objective and Scope of the Report

    2. Market Definition and Overview

    3. Executive Summary

    4. Market Dynamics

    • 4.1. Market Impacting Factors
      • 4.1.1. Drivers
        • 4.1.1.1. The Increasing Burden of Endometriosis and Increasing Awareness
        • 4.1.1.2. Research and Development
      • 4.1.2. Restraints
        • 4.1.2.1. High Developmental Cost
        • 4.1.2.2. Ineffective Drug Therapies
      • 4.1.3. Opportunity
      • 4.1.4. Impact Analysis

    5. Industry Analysis

    • 5.1. Porter's Five Forces Analysis
    • 5.2. Supply Chain Analysis
    • 5.3. Regulatory Analysis
    • 5.4. Pipeline Analysis
    • 5.5. Epidemiological Analysis

    6. COVID-19 Analysis

    • 6.1. Analysis of Covid-19 on the Market
      • 6.1.1. Before COVID-19 Market Scenario
      • 6.1.2. Present COVID-19 Market Scenario
      • 6.1.3. After COVID-19 or Future Scenario
    • 6.2. Pricing Dynamics Amid Covid-19
    • 6.3. Demand-Supply Spectrum
    • 6.4. Government Initiatives Related to the Market During Pandemic
    • 6.5. Manufacturer's Strategic Initiatives
    • 6.6. Conclusion

    7. By Type

    • 7.1. Introduction
      • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      • 7.1.2. Market Attractiveness Index, By Type
    • 7.2. Superficial Peritoneal Lesion
      • 7.2.1. Introduction
      • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.3. Endometrioma
    • 7.4. Deeply Infiltrating Endometriosis
    • 7.5. Others

    8. By Therapy Type

    • 8.1. Introduction
      • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
      • 8.1.2. Market Attractiveness Index, By Therapy Type
    • 8.2. Hormonal Therapy
      • 8.2.1. Introduction
      • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.3. Pain Management
    • 8.4. Others

    9. By Route of Administration

    • 9.1. Introduction
      • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
      • 9.1.2. Market Attractiveness Index, By Route of Administration
    • 9.2. Oral
      • 9.2.1. Introduction
      • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 9.3. Parenteral
    • 9.4. Others

    10. By End User

    • 10.1. Introduction
      • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
      • 10.1.2. Market Attractiveness Index, By End User Segment
    • 10.2. Hospitals And Clinics
      • 10.2.1. Introduction
      • 10.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 10.3. Homecare
    • 10.4. Other

    11. By Region

    • 11.1. Introduction
      • 11.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
      • 11.1.2. Market Attractiveness Index, By Region
    • 11.2. North America
      • 11.2.1. Introduction
      • 11.2.2. Key Region-Specific Dynamics
      • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
      • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
      • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
      • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        • 11.2.7.1. The U.S.
        • 11.2.7.2. Canada
        • 11.2.7.3. Mexico
    • 11.3. Europe
      • 11.3.1. Introduction
      • 11.3.2. Key Region-Specific Dynamics
      • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
      • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
      • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
      • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        • 11.3.7.1. Germany
        • 11.3.7.2. The U.K.
        • 11.3.7.3. France
        • 11.3.7.4. Italy
        • 11.3.7.5. Spain
        • 11.3.7.6. Rest of Europe
    • 11.4. South America
      • 11.4.1. Introduction
      • 11.4.2. Key Region-Specific Dynamics
      • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
      • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
      • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
      • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        • 11.4.7.1. Brazil
        • 11.4.7.2. Argentina
        • 11.4.7.3. Rest of South America
    • 11.5. Asia Pacific
      • 11.5.1. Introduction
      • 11.5.2. Key Region-Specific Dynamics
      • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
      • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
      • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
      • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        • 11.5.7.1. China
        • 11.5.7.2. India
        • 11.5.7.3. Japan
        • 11.5.7.4. Australia
        • 11.5.7.5. Rest of Asia Pacific
    • 11.6. Middle East and Africa
      • 11.6.1. Introduction
      • 11.6.2. Key Region-Specific Dynamics
      • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
      • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
      • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

    12. Competitive Landscape

    • 12.1. Key Developments and Strategies
    • 12.2. Company Share Analysis
    • 12.3. Product Benchmarking

    13. Company Profiles

    • 13.1. AstraZeneca
      • 13.1.1. Company Overview
      • 13.1.2. Product Portfolio and Description
      • 13.1.3. Key Highlights
      • 13.1.4. Financial Overview
    • 13.2. Eli Lilly and Company
    • 13.3. Pfizer Inc.
    • 13.4. Bayer
    • 13.5. Novartis AG
    • 13.6. Merck & Co., Inc.
    • 13.7. Boehringer Ingelheim International GmbH
    • 13.8. Johnson & Johnson Services, INC.
    • 13.9. AbbVie
    • 13.10. GlaxoSmithKline plc.(*LIST NOT EXHAUSTIVE)

    14. DataM Intelligence

    • 14.1. Appendix
    • 14.2. About Us and Services
    • 14.3. Contact Us